IL233592B - The compounds active as p2x4 receptor antagonists and substances containing them for the prevention and treatment of neurogenic pain - Google Patents

The compounds active as p2x4 receptor antagonists and substances containing them for the prevention and treatment of neurogenic pain

Info

Publication number
IL233592B
IL233592B IL233592A IL23359214A IL233592B IL 233592 B IL233592 B IL 233592B IL 233592 A IL233592 A IL 233592A IL 23359214 A IL23359214 A IL 23359214A IL 233592 B IL233592 B IL 233592B
Authority
IL
Israel
Prior art keywords
compounds
prophylactic
therapeutic agent
active ingredients
receptor antagonist
Prior art date
Application number
IL233592A
Other languages
English (en)
Hebrew (he)
Other versions
IL233592A0 (en
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Publication of IL233592A0 publication Critical patent/IL233592A0/en
Publication of IL233592B publication Critical patent/IL233592B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL233592A 2012-01-13 2014-07-10 The compounds active as p2x4 receptor antagonists and substances containing them for the prevention and treatment of neurogenic pain IL233592B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012005343 2012-01-13
PCT/JP2013/050320 WO2013105608A1 (fr) 2012-01-13 2013-01-10 Antagoniste des récepteurs p2x4

Publications (2)

Publication Number Publication Date
IL233592A0 IL233592A0 (en) 2014-08-31
IL233592B true IL233592B (en) 2018-08-30

Family

ID=48781550

Family Applications (1)

Application Number Title Priority Date Filing Date
IL233592A IL233592B (en) 2012-01-13 2014-07-10 The compounds active as p2x4 receptor antagonists and substances containing them for the prevention and treatment of neurogenic pain

Country Status (15)

Country Link
US (6) US9382236B2 (fr)
EP (1) EP2803662B1 (fr)
JP (1) JP6207399B2 (fr)
KR (2) KR102140746B1 (fr)
CN (4) CN104066724B (fr)
AU (1) AU2013208536B2 (fr)
CA (1) CA2861024C (fr)
DK (1) DK2803662T3 (fr)
ES (1) ES2626036T3 (fr)
IL (1) IL233592B (fr)
NZ (1) NZ627878A (fr)
PL (1) PL2803662T3 (fr)
PT (1) PT2803662T (fr)
SG (2) SG10201605325TA (fr)
WO (1) WO2013105608A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6207399B2 (ja) 2012-01-13 2017-10-04 日本ケミファ株式会社 Ｐ２ｘ４受容体拮抗剤
EP3020707B1 (fr) * 2013-07-12 2019-08-21 Nippon Chemiphar Co., Ltd. Antagoniste des récepteurs p2x4
US9873683B2 (en) 2013-07-12 2018-01-23 Nippon Chemiphar Co., Ltd P2X4 receptor antagonist
WO2015088565A1 (fr) * 2013-12-13 2015-06-18 Sunovion Pharmaceuticals Inc. Composés modulateurs du récepteur p2x4 et leurs procédés d'utilisation
WO2016151464A1 (fr) 2015-03-24 2016-09-29 Piramal Enterprises Limited Procédé amélioré de préparation de clobazam et son intermédiaire
WO2016183266A1 (fr) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
EP3449942A4 (fr) * 2016-04-28 2019-12-04 Nippon Chemiphar Co., Ltd. Méthode pour le traitement de la sclérose en plaques
PL3458443T3 (pl) 2016-05-03 2021-03-08 Bayer Pharma Aktiengesellschaft Aromatyczne pochodne sulfonamidowe
WO2018104305A1 (fr) 2016-12-09 2018-06-14 Bayer Pharma Aktiengesellschaft Sulfamoylbenzamides
WO2018104307A1 (fr) 2016-12-09 2018-06-14 Bayer Pharma Aktiengesellschaft Dérivés de sulfonamide aromatiques et leur utilisation en tant qu'anatagon i sts ou des modulateurs allostériques négatifs de p2x4
WO2018210729A1 (fr) 2017-05-18 2018-11-22 Bayer Pharma Aktiengesellschaft Dérivés de sulfonamide aromatiques utilisés en tant qu'antagonistes ou modulateurs allostériques négatifs du récepteur p2x4
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
JP7374882B2 (ja) * 2018-03-14 2023-11-07 日本ケミファ株式会社 咳嗽の治療のための医薬
JP7541483B2 (ja) * 2018-09-03 2024-08-28 日本ケミファ株式会社 糖尿病性末梢神経障害のための医薬
JP2022500466A (ja) 2018-09-21 2022-01-04 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としての官能化複素環
IL283190B2 (en) 2018-11-21 2025-08-01 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
WO2020247444A1 (fr) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Agents antiviraux de l'hépatite b
WO2020247561A1 (fr) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Agents antiviraux de l'hépatite b
WO2020247575A1 (fr) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN115210229A (zh) 2020-01-03 2022-10-18 博格有限责任公司 多环酰胺作为治疗癌症的ube2k调节剂
WO2021188414A1 (fr) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Composés hétérocycliques fonctionnalisés utiles en tant qu'agents antiviraux
CA3174216A1 (fr) * 2020-03-30 2021-10-07 Luca ANTONIOLI Medicament pour prevenir ou traiter le syndrome du colon irritable ou lamaladie inflammatoire de l'intestin
WO2022002860A1 (fr) 2020-06-30 2022-01-06 Bayer Aktiengesellschaft Utilisation de n-phénylacétamides ayant une activité antagoniste du récepteur p2x4 pour le traitement de certains troubles oculaires
JP2023531283A (ja) * 2020-06-30 2023-07-21 バイエル アクチェンゲゼルシャフト Ｐ２ｘ４受容体拮抗作用を有する置換ｎ－フェニルアセトアミド
CA3186937A1 (fr) * 2020-08-03 2022-02-10 Isao Matsuoka Composition pharmaceutique pour la prevention, la suppression ou le traitement de symptomes associes a une reaction allergique
WO2022049253A1 (fr) 2020-09-07 2022-03-10 Bayer Aktiengesellschaft N-hétéroaryl-n-pyridinylacétamides substitués en tant que modulateurs de p2x4
US20240300939A1 (en) 2021-06-14 2024-09-12 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer
IT202100025124A1 (it) 2021-09-30 2023-03-30 Univ Degli Studi Di Firenze Medicamento per uso nel prevenire o trattare il dolore nocicettivo e/o viscerale
CA3233194A1 (fr) 2021-09-30 2023-04-06 Toshiyasu Imai Agent prophylactique ou therapeutique pour des maladies respiratoires
JP2025041993A (ja) * 2022-02-17 2025-03-27 国立大学法人鳥取大学 子宮内膜症又は子宮腺筋症の予防又は治療剤
JPWO2023190826A1 (fr) 2022-03-31 2023-10-05
TW202448478A (zh) 2023-02-24 2024-12-16 日商日本化美化股份有限公司 具有ｐ２ｘ４受體拮抗作用之化合物的固體分散體
WO2025205829A1 (fr) * 2024-03-26 2025-10-02 国立研究開発法人国立循環器病研究センター Composition pharmaceutique pour la prévention ou le traitement d'un anévrisme cérébral

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5534960Y2 (fr) 1977-01-31 1980-08-18
JPS53111093A (en) * 1977-03-07 1978-09-28 Takeda Chem Ind Ltd Imidazo(1,5-d)(1,4)benzodiazepin derivative and its preparation
JPH02304437A (ja) * 1989-05-19 1990-12-18 Konica Corp 新規な写真用カプラー
RU2152939C1 (ru) * 1994-04-14 2000-07-20 Глаксо Веллкам Инк. 5-гетероцикло-1,5-бензодиазепины и их фармацевтически приемлемые соли
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
SE0104250D0 (sv) 2001-12-14 2001-12-14 Astrazeneca Ab Heterocyclic compounds
JP2006509832A (ja) 2002-10-30 2006-03-23 ニューロ３デー サイクリックヌクレオチドホスホジエステラーゼ阻害剤、その調製及び使用
DE10312969A1 (de) 2003-03-24 2004-10-07 Bayer Healthcare Ag Benzofuro-1,4-diazepin-2-on-Derivate
US20050074819A1 (en) 2003-10-01 2005-04-07 Japan Health Sciences Foundation Screening method of drug for treatment of neuropathic pain
KR100512749B1 (ko) 2004-01-14 2005-09-07 삼성전자주식회사 모니터장치
US20100298285A1 (en) 2006-03-16 2010-11-25 Kelly Michael G Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
US20100256123A1 (en) 2006-08-25 2010-10-07 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
JP2012087053A (ja) * 2009-02-03 2012-05-10 Nippon Chemiphar Co Ltd ジアゼピンジオン誘導体
DK2397480T3 (da) 2009-02-16 2013-09-02 Nippon Chemiphar Co Diazepindionderivat
CN103080094B (zh) * 2010-07-13 2015-06-24 日本化学医药株式会社 P2x4受体拮抗剂
JP2013209292A (ja) 2010-07-23 2013-10-10 Nippon Chemiphar Co Ltd Ｐ２ｘ４受容体拮抗剤
JP6325252B2 (ja) * 2011-05-25 2018-05-16 国立大学法人九州大学 ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤
JP6207399B2 (ja) 2012-01-13 2017-10-04 日本ケミファ株式会社 Ｐ２ｘ４受容体拮抗剤

Also Published As

Publication number Publication date
ES2626036T3 (es) 2017-07-21
KR102140746B1 (ko) 2020-08-04
US20200223806A1 (en) 2020-07-16
KR20200032762A (ko) 2020-03-26
EP2803662A4 (fr) 2015-06-03
CA2861024C (fr) 2020-09-22
US20240417379A1 (en) 2024-12-19
JP6207399B2 (ja) 2017-10-04
US20220380322A1 (en) 2022-12-01
US10633349B2 (en) 2020-04-28
CN104066724B (zh) 2020-04-17
PT2803662T (pt) 2017-04-05
EP2803662A1 (fr) 2014-11-19
DK2803662T3 (en) 2017-05-01
WO2013105608A1 (fr) 2013-07-18
JPWO2013105608A1 (ja) 2015-05-11
US20180201587A1 (en) 2018-07-19
NZ627878A (en) 2016-03-31
CN111333588A (zh) 2020-06-26
CN108863959A (zh) 2018-11-23
SG10201605325TA (en) 2016-08-30
US9382236B2 (en) 2016-07-05
AU2013208536B2 (en) 2017-07-20
HK1203191A1 (en) 2015-10-23
CN104066724A (zh) 2014-09-24
EP2803662B1 (fr) 2017-03-01
US20160280667A1 (en) 2016-09-29
US9969700B2 (en) 2018-05-15
KR102092147B1 (ko) 2020-03-23
US20140357858A1 (en) 2014-12-04
AU2013208536A1 (en) 2014-08-21
PL2803662T3 (pl) 2017-09-29
CN110483423A (zh) 2019-11-22
KR20140116926A (ko) 2014-10-06
CA2861024A1 (fr) 2013-07-18
US12116351B2 (en) 2024-10-15
CN108863959B (zh) 2021-11-30
IL233592A0 (en) 2014-08-31
US11434207B2 (en) 2022-09-06
SG11201404030YA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
IL233592B (en) The compounds active as p2x4 receptor antagonists and substances containing them for the prevention and treatment of neurogenic pain
ZA202003200B (en) Compositions, methods, and systems for the synthesis and use of imaging agents
PL2629754T3 (pl) Kompozycja farmaceutyczna w postaci ciekłej do podawania składników czynnych
IL235923B (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
ZA201406145B (en) Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL230528A0 (en) An abuse-resistant pharmaceutical preparation for the treatment of opioid addiction
IL230463A (en) Benzamides, their preparation and their pharmaceutical preparations
EP2925340A4 (fr) Compositions pharmaceutiques comprenant des agonistes sélectifs du récepteur de la mélanocortine 1, et méthodes thérapeutiques d'utilisation de ces compositions
PL2841549T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
PL2841548T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
IL235830A0 (en) New dosage and formulation
ZA201306905B (en) Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these
IL236466B (en) Pharmaceutical composition for the release of active components
PT2846839T (pt) Formulações para a administração de ingredientes ativos
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
SI2662382T1 (sl) Sterolni derivativi, njihova priprava, farmacevtske sestave, ki jih vsebujejo, in njihova uporaba za zdravljenje več glioblastomov
EP2701689A4 (fr) Compositions pharmaceutiques de raltégravir, procédés de préparation et utilisation de celles-ci
LT2704698T (lt) Vaisto forma, skirta aktyvių ingredientų kontroliuojamam atpalaidavimui
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия
GB201207102D0 (en) CRHR1 antagonists for use in the treatment of patients having CRH overactivity

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed